Eating Disorders in Type 1 Insulin-dependent Diabetes Patients
NCT ID: NCT04506216
Last Updated: 2022-04-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
200 participants
INTERVENTIONAL
2020-09-01
2021-12-23
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Eating Disturbances in Patients With Type 1 Diabetes Initiating Insulin Therapy
NCT07151924
Impact of Dietary Knowledge Related to Functional Insulin Therapy in Type 1 Diabetes on the Risk of Eating Disorders
NCT07021456
Develop and Validate a Self-Administered Instrument That Will Screen for Eating Disorder Symptoms in Persons Aged 12 and Older With Type 1 Diabetes.
NCT00948311
Postprandial Gut Hormone Responses in Patients With Type 1 Diabetes Mellitus
NCT04430946
Individualised Postprandial Glucose Responses in Type 1 Diabetes
NCT05231642
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Therefore the terminology diaboulimia has emerged to characterize an eating disorder specific to type 1 insulin-dependent diabetes patients, with insulin under dosage with a view of losing or controlling weight and that can contribute to a deterioration of the body composition.
The purpose of this study is to determine the prevalence of eating disorders in an adult cohort with type 1 insulin-dependent diabetes.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
cohort
adult patients with type 1 diabetes and insulin pump treatment . Duration of participation: 30 minutes
cohort
During a regular follow-up visit, the following data will be collected:
* questionnaires on lifestyle, eating custom (SCOFF-F, 5th question of the m-SCOFF) and physical activity (IPAQ)
* bio-electric impedance analysis
* insulin pump and sensor data collection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
cohort
During a regular follow-up visit, the following data will be collected:
* questionnaires on lifestyle, eating custom (SCOFF-F, 5th question of the m-SCOFF) and physical activity (IPAQ)
* bio-electric impedance analysis
* insulin pump and sensor data collection
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient followed up for a subcutaneous insulin pump treatment by the healthcare provider, participating in the study (Agir à Dom group).
* Beneficiary of social security coverage.
Exclusion Criteria
* Patient wearing a pacemaker
* Breastfeeding or pregnant woman
* Deprived of liberty by judicial or administrative decision
* Legal guardianship
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AGIR à Dom
OTHER
Icadom
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Cécile Bétry, PhD
Role: PRINCIPAL_INVESTIGATOR
CHU Grenoble Alpes
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
AGIR à dom.
Meylan, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2020-A00147-32
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.